Top

Supportive Care in Cancer

Published in:

01-10-2014 | Letter to the editor

Cancer-related fatigue: can it be due to adrenal suppression secondary to high-dose steroids used as antiemetic?

Authors: Orhan Onder Eren, Mehmet Akif Ozturk, Basak Oyan

Published in: Supportive Care in Cancer | Issue 10/2014

Excerpt

To the editor: …

Yennurajalingam S, Frisbee-Hume S, Palmer JL et al (2013) Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25):3076–82PubMedCrossRef

Scott HR, McMillan DC, Forrest LM et al (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87(3):264–7PubMedCentralPubMedCrossRef

Morrow GR, Andrews PL, Hickok JT et al (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10(5):389–98PubMedCrossRef

Lundström S, Fürst CJ (2003) Symptoms in advanced cancer: relationship to endogenous cortisol levels. Palliat Med 17(6):503–8PubMedCrossRef

Basch E, Prestrud AA, Hesketh PJ et al (2011) American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–98PubMedCrossRef

Henzen C, Suter A, Lerch E et al (2000) Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 355(9203):542–5PubMedCrossRef

Han HS, Shim YK, Kim JE et al (2012) A pilot study of adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients. Support Care Cancer 20(7):1565–72PubMedCrossRef

Meikle AW, Tyler FH (1977) Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 63(2):200–7PubMedCrossRef

Title: Cancer-related fatigue: can it be due to adrenal suppression secondary to high-dose steroids used as antiemetic?
Authors: Orhan Onder Eren
Mehmet Akif Ozturk
Basak Oyan
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 10/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2124-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2014

Characteristics of taste and smell alterations reported by patients after starting treatment for lung cancer

A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes

Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients

Erratum to: Evaluation of multiplex PCR in first episodes of febrile neutropenia as a tool to improve early yeast diagnosis in leukemic/preleukemic patients

Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study

Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer